# Dina Stroopinsky

## List of Publications by Year
in descending order

| | | | |
|---|---|---|---|
| **57** papers | **975** citations | 516561<br>**16** h-index | 454834<br>**30** g-index |
| **57** all docs | **57** docs citations | **57** times ranked | **1784** citing authors |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1 | Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth *In Vitro* and *In Vivo*. Clinical Cancer Research, 2021, 27, 1139-1149. | 3.2 | 76 |
| 2 | Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica, 2021, 106, 1330-1342. | 1.7 | 19 |
| 3 | Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T. Blood, 2021, 138, 2786-2786. | 0.6 | 1 |
| 4 | Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager (CD123-CODV-TCE) for Treatment of Acute Myeloid Leukemia. Blood, 2021, 138, 904-904. | 0.6 | 0 |
| 5 | Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease. Blood, 2021, 138, 264-264. | 0.6 | 3 |
| 6 | Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT) Tj ETQq0 0 0rgBT /Overlock 10 T | 0.6 | 2 |
| 7 | Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse. Blood, 2021, 138, 2830-2830. | 0.6 | 1 |
| 8 | Synergism between CAR-T Cells and a Personalized Tumor Vaccine in Hematological Malignances. Blood, 2021, 138, 737-737. | 0.6 | 0 |
| 9 | Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Science Translational Medicine, 2021, 13, eabh1962. | 5.8 | 49 |
| 10 | Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial. Blood, 2020, 136, 10-10. | 0.6 | 0 |
| 11 | Epsteinâˆ'Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia, 2019, 33, 132-147. | 3.3 | 126 |
| 12 | Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Research, 2019, 29, 446-459. | 5.7 | 32 |
| 13 | Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine. British Journal of Haematology, 2019, 185, 679-690. | 1.2 | 52 |
| 14 | CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model. Blood, 2019, 134, 1386-1386. | 0.6 | 2 |
| 15 | Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma. Blood, 2019, 134, 392-392. | 0.6 | 2 |
| 16 | T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy. Blood, 2019, 134, 2673-2673. | 0.6 | 2 |
| 17 | Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine. Blood, 2019, 134, 3832-3832. | 0.6 | 0 |
| 18 | Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies. Blood, 2019, 134, 3227-3227. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 19 | Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood, 2018, 131, 2836-2845. | 0.6 | 30 |
| 20 | A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. American Journal of Hematology, 2018, 93, 254-261. | 2.0 | 12 |
| 21 | MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. Journal of Cellular and Molecular Medicine, 2018, 22, 3887-3898. | 1.6 | 12 |
| 22 | Ex-Vivo Stimulation with DC/AML Fusion Vaccine in the Presence of Cytokines Leads to an Activated T Cell Memory Phenotype and Enhanced Cytotoxicity with Potential for Use As an Adoptive Cellular Therapy. Blood, 2018, 132, 2728-2728. | 0.6 | 1 |
| 23 | A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model. Blood, 2018, 132, 1446-1446. | 0.6 | 2 |
| 24 | MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood, 2017, 129, 1791-1801. | 0.6 | 130 |
| 25 | Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein <scp>MUC</scp>1. British Journal of Haematology, 2017, 176, 929-938. | 1.2 | 34 |
| 26 | Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Molecular Cancer Therapeutics, 2017, 16, 2304-2314. | 1.9 | 10 |
| 27 | Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Science Translational Medicine, 2016, 8, 368ra171. | 5.8 | 140 |
| 28 | MUC1 in hematological malignancies. Leukemia and Lymphoma, 2016, 57, 2489-2498. | 0.6 | 22 |
| 29 | Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease. Blood, 2016, 128, 387-387. | 0.6 | 2 |
| 30 | MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget, 2016, 7, 38974-38987. | 0.8 | 36 |
| 31 | Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Blood, 2016, 128, 4175-4175. | 0.6 | 0 |
| 32 | MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs. Blood, 2016, 128, 2871-2871. | 0.6 | 1 |
| 33 | Acute Myeloid Leukemia Cells Export c-Myc in Extracellular Vesicles Driving a Proliferation of Immune-Suppressive Myeloid-Derived Suppressor Cells. Blood, 2016, 128, 703-703. | 0.6 | 0 |
| 34 | A Novel Dendritic Cell-Derived Vaccine in Multiple Myeloma. Blood, 2016, 128, 4484-4484. | 0.6 | 0 |
| 35 | Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood, 2015, 126, 354-362. | 0.6 | 31 |
| 36 | MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia. Blood, 2015, 126, 2473-2473. | 0.6 | 2 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 37 | DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions. Blood, 2015, 126, 2549-2549. | 0.6 | 5 |
| 38 | Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease. Blood, 2015, 126, 4218-4218. | 0.6 | 10 |
| 39 | MUC-1 Regulates MiR34a Expression in Acute Myeloid Leukemia Cells Resulting in an Accumulation of Granulocytic Myeloid-Derived Suppressor Cells. Blood, 2015, 126, 643-643. | 0.6 | 0 |
| 40 | Immunomodulatory Effect of MUC1-C in Acute Myeloid Leukemia. Blood, 2015, 126, 3659-3659. | 0.6 | 0 |
| 41 | MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood, 2014, 123, 734-742. | 0.6 | 16 |
| 42 | Mucin-1 (MUC1) Oncoprotein in Multiple Myeloma Cells Inhibits the Th1 Responses By Down Regulating the Expression of Mir-200c and up-Regulating the PDL1 Expression. Blood, 2014, 124, 2072-2072. | 0.6 | 3 |
| 43 | MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. Blood, 2014, 124, 808-808. | 0.6 | 0 |
| 44 | Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML). Blood, 2014, 124, 2303-2303. | 0.6 | 0 |
| 45 | Myeloid-Derived Suppressor Cells Are Expanded in Patients with AML and Are Dependent on MUC1 Expression. Blood, 2014, 124, 226-226. | 0.6 | 0 |
| 46 | Bone Marrow Stroma Protects Myeloma Cells from Cytotoxic Damage Via Induction of the Oncoprotein MUC1. Blood, 2014, 124, 3378-3378. | 0.6 | 0 |
| 47 | MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells. Cancer Research, 2013, 73, 5569-5579. | 0.4 | 49 |
| 48 | Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients. Blood, 2013, 122, 3928-3928. | 0.6 | 7 |
| 49 | STAT3 Inhibition Promotes Potent Th1 Responses By Down Regulating Pdl-1 Expression On Tumor Cells. Blood, 2013, 122, 3217-3217. | 0.6 | 0 |
| 50 | Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential. Blood, 2013, 122, 127-127. | 0.6 | 0 |
| 51 | Targeting Leukemia Initiating Cells by MUC1-C Subunit Inhibition. Blood, 2012, 120, 3583-3583. | 0.6 | 0 |
| 52 | Transduction of Malignant Plasma Cells with Three Costimulatory Molecules (TRICOM) Elicits Myeloma-Specific Immune Response in Vitro – a Promising Strategy for Immunotherapy. Blood, 2012, 120, 1908-1908. | 0.6 | 35 |
| 53 | Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission. Blood, 2011, 118, 948-948. | 0.6 | 3 |
| 54 | MUC1 Inhibition Reverses the Poor Immunogenicity of Leukemia Stem Cells Rendering Them Susceptible to Immunotherapy. Blood, 2011, 118, 1883-1883. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 55 | Addition of Clofarabine to TLI/ATG Conditioning: Impact on Immune Reconstitution and Clinical Outcomes,. Blood, 2011, 118, 4066-4066. | 0.6 | 0 |
| 56 | Lenalidomide Decreases PD-1 Expression, Depletes Regulatory T-Cells and Improves Cellular Response to a Multiple Myeloma/Dendritic Cell Fusion Vaccine In Vitro. Blood, 2010, 116, 492-492. | 0.6 | 13 |
| 57 | Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition. Blood, 2010, 116, 848-848. | 0.6 | 1 |